GlycoMimetics, Inc. (GLYC)
NASDAQ: GLYC · IEX Real-Time Price · USD
1.830
+0.110 (6.40%)
At close: May 3, 2024, 4:00 PM
1.840
+0.010 (0.55%)
After-hours: May 3, 2024, 7:58 PM EDT
GlycoMimetics Revenue
In the year 2023, GlycoMimetics had annual revenue of $10.00K, a decrease of -86.67%. Revenue in the quarter ending December 31, 2023 was $10.00K.
Revenue (ttm)
$10.00K
Revenue Growth
-86.67%
P/S Ratio
11,794.42
Revenue / Employee
$286
Employees
35
Market Cap
117.94M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 10.00K | -65.00K | -86.67% |
Dec 31, 2022 | 75.00K | -1.08M | -93.53% |
Dec 31, 2021 | 1.16M | -9.00M | -88.59% |
Dec 31, 2020 | 10.16M | - | - |
Dec 31, 2019 | 0 | - | - |
Dec 31, 2018 | 0 | - | - |
Dec 31, 2017 | 0 | - | - |
Dec 31, 2016 | 18.50K | -20.05M | -99.91% |
Dec 31, 2015 | 20.07M | 5.04M | 33.56% |
Dec 31, 2014 | 15.03M | 11.03M | 276.37% |
Dec 31, 2013 | 3.99M | -11.26M | -73.83% |
Dec 31, 2012 | 15.26M | 11.44M | 300.04% |
Dec 31, 2011 | 3.81M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Inotiv | 585.17M |
Aurora Cannabis | 200.73M |
FibroGen | 147.75M |
Xtant Medical Holdings | 91.30M |
KORU Medical Systems | 29.32M |
Myomo | 19.24M |
Abeona Therapeutics | 3.50M |
aTyr Pharma | 588.00K |
GLYC News
- 10 days ago - GlycoMimetics to Report First Quarter 2024 Financial Results on May 9, 2024 - Business Wire
- 5 weeks ago - GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2023 - Business Wire
- 7 weeks ago - GlycoMimetics to Report Fourth Quarter and 2023 Full Year Financial Results on March 27, 2024 - Business Wire
- 2 months ago - GlycoMimetics to Participate in Upcoming Cowen 44th Annual Health Care Conference - Business Wire
- 2 months ago - GlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) - Business Wire
- 4 months ago - GlycoMimetics Announces Positive Initial Safety and Pharmacokinetic Results from Phase 1a Healthy Volunteer Study of GMI-1687 - Business Wire
- 5 months ago - GlycoMimetics Announces Independent Presentations on Uproleselan at American Society of Hematology Annual Meeting including New Clinical Data in Treated Secondary Acute Myeloid Leukemia - Business Wire
- 6 months ago - GlycoMimetics to Participate in Upcoming Jefferies London Healthcare Conference - Business Wire